137 related articles for article (PubMed ID: 37954718)
1. Ten-Fold Elevation of Chromogranin A Level Unrelated to a Neuroendocrine Tumor: A Case Report of the Diagnostic Interference of Proton Pump Inhibitors.
Alkhayat MJ; Davis K; Atkins SJ; Sheikh AA; Saif MW
Cureus; 2023 Oct; 15(10):e46862. PubMed ID: 37954718
[TBL] [Abstract][Full Text] [Related]
2. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.
Al-Risi ES; Al-Essry FS; Mula-Abed WS
Oman Med J; 2017 Sep; 32(5):365-370. PubMed ID: 29026467
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.
Korse CM; Muller M; Taal BG
Br J Cancer; 2011 Oct; 105(8):1173-5. PubMed ID: 21989216
[TBL] [Abstract][Full Text] [Related]
5. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
6. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors.
Baekdal J; Krogh J; Klose M; Holmager P; Langer SW; Oturai P; Kjaer A; Federspiel B; Hilsted L; Rehfeld JF; Knigge U; Andreassen M
Diagnostics (Basel); 2020 Oct; 10(11):. PubMed ID: 33138020
[TBL] [Abstract][Full Text] [Related]
7. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.
Modlin IM; Aslanian H; Bodei L; Drozdov I; Kidd M
Endocr Connect; 2014 Dec; 3(4):215-23. PubMed ID: 25316294
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNA Increases the Diagnostic Accuracy of Chromogranin A in Metastatic Pancreatic Neuroendocrine Tumors.
Kövesdi A; Kurucz PA; Nyírő G; Darvasi O; Patócs A; Butz H
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32887459
[TBL] [Abstract][Full Text] [Related]
9. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects.
Mosli HH; Dennis A; Kocha W; Asher LJ; Van Uum SH
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1731-5. PubMed ID: 22723311
[TBL] [Abstract][Full Text] [Related]
10. [Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].
Glinicki P; Jeske W
Endokrynol Pol; 2011; 62 Suppl 1():25-8. PubMed ID: 22125107
[TBL] [Abstract][Full Text] [Related]
11. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
12. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
13. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system.
van der Knaap RHP; Kwekkeboom DJ; Ramakers CRB; de Rijke YB
Pract Lab Med; 2015 Apr; 1():5-11. PubMed ID: 28932793
[TBL] [Abstract][Full Text] [Related]
15. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.
Giusti M; Sidoti M; Augeri C; Rabitti C; Minuto F
Eur J Endocrinol; 2004 Mar; 150(3):299-303. PubMed ID: 15012614
[TBL] [Abstract][Full Text] [Related]
16. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.
Cimitan M; Buonadonna A; Cannizzaro R; Canzonieri V; Borsatti E; Ruffo R; De Apollonia L
Ann Oncol; 2003 Jul; 14(7):1135-41. PubMed ID: 12853358
[TBL] [Abstract][Full Text] [Related]
18. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.
Hijioka M; Ito T; Igarashi H; Fujimori N; Lee L; Nakamura T; Jensen RT; Takayanagi R
Cancer Sci; 2014 Nov; 105(11):1464-71. PubMed ID: 25220535
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
20. Case report: extreme CgA elevation under PPI confounding assessment of adrenal mass.
Wiedmann MW; Mössner J; Stumvoll M; Führer D
Z Gastroenterol; 2009 Jul; 47(7):671-3. PubMed ID: 19606410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
